Fixed Duration Combination Therapy with Carfilzomib, Lenalidomide, and Dexamethasone Followed By Lenalidomide Maintenance Leads to High Rates of Sustained MRD Negativity in Patients with High-Risk Smoldering Multiple Myeloma: Long Term Follow up of an Investigator Initiated Phase 2 TrialElizabeth Hill, Dickran Kazandjian, Ani Petrosyan et al.|Blood|2023Cited by 6
A Phase 2 Response-Adapted Study of Daratumumab, Carfilzomib, and Dexamethasone (DKd) in Patients with High-Risk Smoldering Multiple MyelomaRoshani Patel, Elizabeth Hill, Amrit Bhaskarla et al.|Blood|2024Cited by 0
Primary Results from a Phase 2 Response-Adapted Study of Daratumumab, Carfilzomib, and Dexamethasone (DKd) in Patients with High-Risk Smoldering Multiple MyelomaRoshani Patel, Elizabeth Hill, Max J. Gordon et al.|Clinical Lymphoma Myeloma & Leukemia|2025Cited by 0